# ADAPTela (NCT07242352)

> Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07242352
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Women's Cancer Study Group GmbH
- Conditions: Breast Cancer; HR+/HER2- Breast Cancer
- Interventions: Elacestrant; Standard-of-care endocrine treatment
- Enrollment: 1520
- Primary outcome: 5-year invasive disease-free survival (iDFS)

## Indexed commentary on ADAPTela so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=adaptela-nct07242352